| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 产品销售收入(元) | 483,168,069.99 | - | 614,022,476.05 | - | 526,371,791.39 |
| 技术收入(元) | - | 39,217,681.72 | - | 75,804,793.09 | 25,993,598.11 |
| 权益分成收入(元) | - | 60,036,773.87 | - | 61,903,401.02 | 31,736,060.69 |
| 抗病毒类(元) | - | 174,411,201.50 | - | 280,948,940.90 | - |
| 抗真菌类(元) | - | 407,165,738.06 | - | 254,028,874.81 | - |
| 免疫抑制类(元) | - | 82,043,290.31 | - | 56,302,854.81 | - |
| 制剂类(元) | - | 161,149,894.50 | - | 138,009,537.22 | - |
| 技术权益及服务收入(元) | 36,362,001.79 | - | 29,766,533.40 | - | - |
| 其他类产品(元) | - | 324,256,954.02 | - | 294,178,132.01 | - |
| 营业成本(元) | |||||
| 产品销售收入(元) | 259,712,577.07 | - | 283,869,053.93 | - | 250,600,521.64 |
| 技术收入(元) | - | 18,173,525.70 | - | 20,975,623.82 | 5,737,730.95 |
| 权益分成收入(元) | - | - | - | - | - |
| 抗病毒类(元) | - | 116,638,603.64 | - | 181,057,256.80 | - |
| 抗真菌类(元) | - | 104,538,142.32 | - | 70,362,335.41 | - |
| 免疫抑制类(元) | - | 39,175,642.38 | - | 29,644,044.62 | - |
| 制剂类(元) | - | 57,134,870.54 | - | 45,576,070.92 | - |
| 技术权益及服务收入(元) | 1,605,582.02 | - | 453,995.19 | - | - |
| 其他类产品(元) | - | 180,939,841.86 | - | 161,973,053.50 | - |
| 毛利(元) | |||||
| 产品销售收入(元) | 223,455,492.92 | - | 330,153,422.12 | - | 275,771,269.75 |
| 技术收入(元) | - | 21,044,156.02 | - | 54,829,169.27 | 20,255,867.16 |
| 权益分成收入(元) | - | 60,036,773.87 | - | 61,903,401.02 | 31,736,060.69 |
| 抗病毒类(元) | - | 57,772,597.86 | - | 99,891,684.10 | - |
| 抗真菌类(元) | - | 302,627,595.74 | - | 183,666,539.40 | - |
| 免疫抑制类(元) | - | 42,867,647.93 | - | 26,658,810.19 | - |
| 制剂类(元) | - | 104,015,023.96 | - | 92,433,466.30 | - |
| 技术权益及服务收入(元) | 34,756,419.77 | - | 29,312,538.21 | - | - |
| 其他类产品(元) | - | 143,317,112.16 | - | 132,205,078.51 | - |
| 毛利率(%) | |||||
| 产品销售收入(%) | 46.25 | - | 53.77 | - | 52.39 |
| 技术收入(%) | - | 53.66 | - | 72.33 | 77.93 |
| 权益分成收入(%) | - | - | - | - | - |
| 抗病毒类(%) | - | 33.12 | - | 35.56 | - |
| 抗真菌类(%) | - | 74.33 | - | 72.30 | - |
| 免疫抑制类(%) | - | 52.25 | - | 47.35 | - |
| 制剂类(%) | - | 64.55 | - | 66.98 | - |
| 技术权益及服务收入(%) | 95.58 | - | 98.47 | - | - |
| 其他类产品(%) | - | 44.20 | - | 44.94 | - |
| 收入构成(%) | |||||
| 产品销售收入(%) | 93.00 | - | 95.38 | - | 90.12 |
| 技术收入(%) | - | 3.14 | - | 6.53 | 4.45 |
| 权益分成收入(%) | - | 4.81 | - | 5.33 | 5.43 |
| 抗病毒类(%) | - | 13.97 | - | 24.20 | - |
| 抗真菌类(%) | - | 32.62 | - | 21.88 | - |
| 免疫抑制类(%) | - | 6.57 | - | 4.85 | - |
| 制剂类(%) | - | 12.91 | - | 11.89 | - |
| 技术权益及服务收入(%) | 7.00 | - | 4.62 | - | - |
| 其他类产品(%) | - | 25.98 | - | 25.33 | - |
| 毛利构成(%) | |||||
| 产品销售收入(%) | 86.54 | - | 91.85 | - | 84.14 |
| 技术收入(%) | - | 2.88 | - | 8.41 | 6.18 |
| 权益分成收入(%) | - | 8.21 | - | 9.50 | 9.68 |
| 抗病毒类(%) | - | 7.90 | - | 15.33 | - |
| 抗真菌类(%) | - | 41.36 | - | 28.19 | - |
| 免疫抑制类(%) | - | 5.86 | - | 4.09 | - |
| 制剂类(%) | - | 14.22 | - | 14.19 | - |
| 技术权益及服务收入(%) | 13.46 | - | 8.15 | - | - |
| 其他类产品(%) | - | 19.59 | - | 20.29 | - |